This clinical trial is focused on studying the effects of a medication called Dapagliflozin on a condition known as Alport syndrome. Alport syndrome is a genetic disorder that affects the kidneys, leading to chronic kidney disease. The trial aims to see if Dapagliflozin can help slow down the progression of kidney disease in adolescents and young adults who have this condition. Dapagliflozin is a type of medication known as a sodium-glucose co-transporter-2 inhibitor, which is often used to manage blood sugar levels in people with diabetes but is being tested here for its potential benefits on kidney health.

Participants in the study will be randomly assigned to receive either Dapagliflozin or a placebo, which is a tablet that looks like the medication but does not contain the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the actual medication and who is receiving the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The trial will last for about 48 weeks, during which time participants will take the tablets orally and have regular check-ups to monitor their kidney function and overall health.

The main goal of the study is to determine if Dapagliflozin can prevent the worsening of kidney disease in people with Alport syndrome by reducing the amount of protein in the urine, a condition known as albuminuria. If successful, this could lead to new treatment recommendations for young people with Alport syndrome, potentially improving their quality of life by delaying the progression to more severe kidney disease. Participants will be closely monitored throughout the study to ensure their safety and to gather important data on the effects of the medication.